Form 4: Centessa Pharmaceuticals Executive Sells Shares Under 10b5-1 Plan

Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals, sold 10,000 ordinary shares at an average price of $16.3386, while also exercising options to acquire 10,000 shares at $3.85.

Summary

• Gregory M. Weinhoff, the Chief Business Officer of Centessa Pharmaceuticals plc, reported changes in beneficial ownership of the company's ordinary shares.
• On March 25, 2025, Weinhoff exercised options to acquire 10,000 ordinary shares at a price of $3.85 per share.
• Simultaneously, Weinhoff sold 10,000 ordinary shares at a weighted average price of $16.3386 per share, with individual sales ranging from $16.16 to $16.53.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 22, 2024.
• Following these transactions, Weinhoff directly owns 134,021 ordinary shares and options to acquire 85,000 ordinary shares.

Sentiment

Score: 5

Explanation: Neutral sentiment. This is a standard disclosure of insider trading activity under a pre-arranged plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The market will likely interpret this as a standard executive compensation activity.

Comparison to Industry Standards

• Executive stock option exercises and sales are common in the pharmaceutical industry.
• Companies like Amgen, Gilead, and Regeneron regularly see similar filings from their executives.
• The use of 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations.
• The size of the transaction (10,000 shares) is relatively small compared to the overall market capitalization of Centessa Pharmaceuticals.

Stakeholder Impact

• The transaction is unlikely to have a significant impact on shareholders, as it's a relatively small volume of shares being traded by an executive.
• Employees may view this as a standard part of executive compensation.
• Customers, suppliers, and creditors are unlikely to be directly affected by this transaction.

Key Dates

Keywords

Centessa Pharmaceuticals, Gregory Weinhoff, insider trading, Form 4, CNTA, share sale, Rule 10b5-1, executive compensation, stock options, beneficial ownership